JP2009539916A - ステージＩＶの悪性黒色腫の処置のための医薬品の製造のためのチモシンα１の使用 - Google Patents

ステージＩＶの悪性黒色腫の処置のための医薬品の製造のためのチモシンα１の使用 Download PDF

Info

Publication number
JP2009539916A
JP2009539916A JP2009514721A JP2009514721A JP2009539916A JP 2009539916 A JP2009539916 A JP 2009539916A JP 2009514721 A JP2009514721 A JP 2009514721A JP 2009514721 A JP2009514721 A JP 2009514721A JP 2009539916 A JP2009539916 A JP 2009539916A
Authority
JP
Japan
Prior art keywords
administered
dose
day
dacarbazine
thymosin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009514721A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009539916A5 (https=
Inventor
カメリーニ・ロベルト
パオロ・カルミナーティ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/424,475 external-priority patent/US20070292392A1/en
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of JP2009539916A publication Critical patent/JP2009539916A/ja
Publication of JP2009539916A5 publication Critical patent/JP2009539916A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/32—Thymopoietins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2009514721A 2006-06-15 2007-04-17 ステージＩＶの悪性黒色腫の処置のための医薬品の製造のためのチモシンα１の使用 Withdrawn JP2009539916A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/424,475 US20070292392A1 (en) 2006-06-15 2006-06-15 Use of thymosin alpha 1 for preparing a medicament for the treatment of stage iv malignant melanoma
US11/734,592 US8017129B2 (en) 2006-06-15 2007-04-12 Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma
PCT/EP2007/053712 WO2007144218A1 (en) 2006-06-15 2007-04-17 Use of thymosin alpha 1 for preparing a medicament for the treatment of stage iv malignant melanoma

Publications (2)

Publication Number Publication Date
JP2009539916A true JP2009539916A (ja) 2009-11-19
JP2009539916A5 JP2009539916A5 (https=) 2010-06-03

Family

ID=38323947

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009514721A Withdrawn JP2009539916A (ja) 2006-06-15 2007-04-17 ステージＩＶの悪性黒色腫の処置のための医薬品の製造のためのチモシンα１の使用

Country Status (14)

Country Link
US (2) US8017129B2 (https=)
EP (1) EP2032153A1 (https=)
JP (1) JP2009539916A (https=)
KR (1) KR20090020646A (https=)
AR (1) AR061352A1 (https=)
AU (1) AU2007260145A1 (https=)
CA (1) CA2652516A1 (https=)
HR (1) HRP20090010A2 (https=)
IL (1) IL195955A0 (https=)
MX (1) MX2008015145A (https=)
NO (1) NO20090238L (https=)
RU (1) RU2009101026A (https=)
TW (1) TW200808327A (https=)
WO (1) WO2007144218A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012505677A (ja) * 2008-10-16 2012-03-08 オリオン テック アンシュタルト 重金属を含む液体廃棄物の処理
JP2018511650A (ja) * 2015-02-09 2018-04-26 ロマーニ、ルイジーナ 嚢胞性線維症の治療における使用のためのチモシンα１

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7260764B2 (en) * 2002-11-26 2007-08-21 Qualcomm Incorporated Multi-channel transmission and reception with block coding in a communication system
US20080300166A1 (en) * 2007-06-01 2008-12-04 Sciclone Pharmaceuticals, Inc. Treatment of Melanoma with Alpha Thymosin Peptides
US20100317583A1 (en) * 2007-12-14 2010-12-16 Sciclone Pharmaceuticals, Inc. Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (hsaa)
US9861833B1 (en) * 2017-03-30 2018-01-09 Norman H. Anderson Methods of treating melanoma

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888980A (en) * 1994-06-30 1999-03-30 Bio-Logic Research And Development Corporation Compositions for enhancing immune function
US5632983A (en) 1994-11-17 1997-05-27 University Of South Florida Method for treating secondary immunodeficiency
US5728707A (en) 1995-07-21 1998-03-17 Constantia Gruppe Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide
US6462017B1 (en) * 2000-05-01 2002-10-08 Sciclone Pharmaceuticals, Inc. Method of reducing side effects of chemotherapy in cancer patients
US7208167B2 (en) * 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
UA80957C2 (en) 2001-11-01 2007-11-26 Sciclone Pharmaceuticals Inc Method of administering a thymosin alpha 1 peptide
UA78726C2 (en) 2001-11-01 2007-04-25 Sciclone Pharmaceuticals Inc Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
US7101598B2 (en) 2002-05-22 2006-09-05 Om Nova Solutions Inc. Self adhering membrane for roofing applications
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
US20080300166A1 (en) 2007-06-01 2008-12-04 Sciclone Pharmaceuticals, Inc. Treatment of Melanoma with Alpha Thymosin Peptides

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012505677A (ja) * 2008-10-16 2012-03-08 オリオン テック アンシュタルト 重金属を含む液体廃棄物の処理
JP2018511650A (ja) * 2015-02-09 2018-04-26 ロマーニ、ルイジーナ 嚢胞性線維症の治療における使用のためのチモシンα１
JP2020196749A (ja) * 2015-02-09 2020-12-10 サイクローン ファーマシューティカルズ インターナショナル リミテッド 嚢胞性線維症の治療における使用のためのチモシンα１
JP7102475B2 (ja) 2015-02-09 2022-07-19 サイクローン ファーマシューティカルズ インターナショナル リミテッド 嚢胞性線維症の治療における使用のためのチモシンα１
JP2022133412A (ja) * 2015-02-09 2022-09-13 サイクローン ファーマシューティカルズ インターナショナル リミテッド 嚢胞性線維症の治療における使用のためのチモシンα１
US11524056B2 (en) 2015-02-09 2022-12-13 Sciclone Pharmaceuticals International Ltd. Thymosin alpha 1 for use in treatment of cystic fibrosis
US12083165B2 (en) 2015-02-09 2024-09-10 Sciclone Pharmaceuticals International (Sg) Pte. Ltd. Thymosin alpha 1 for use in treatment of cystic fibrosis

Also Published As

Publication number Publication date
EP2032153A1 (en) 2009-03-11
US20070292393A1 (en) 2007-12-20
US8017129B2 (en) 2011-09-13
KR20090020646A (ko) 2009-02-26
NO20090238L (no) 2009-03-10
IL195955A0 (en) 2009-09-01
AU2007260145A1 (en) 2007-12-21
RU2009101026A (ru) 2010-07-20
HRP20090010A2 (en) 2009-02-28
AR061352A1 (es) 2008-08-20
CA2652516A1 (en) 2007-12-21
WO2007144218A1 (en) 2007-12-21
TW200808327A (en) 2008-02-16
US20090186000A1 (en) 2009-07-23
MX2008015145A (es) 2008-12-15
US8029799B2 (en) 2011-10-04

Similar Documents

Publication Publication Date Title
US20010018445A1 (en) Pharmaceutical composition for the treatment of hepatocellular carcinoma
JP2011068696A (ja) 腎細胞腫を治療するためのＣＧ２５０およびＩＬ−２またはＩＦＮ−αを含有する抗腫瘍剤
JP2009539916A (ja) ステージＩＶの悪性黒色腫の処置のための医薬品の製造のためのチモシンα１の使用
Bukowski et al. Clinical practice guidelines: renal cell carcinoma
Ellerhorst et al. Phase II trial of low dose γ-interferon in metastatic renal cell carcinoma
Droller Immunotherapy of metastatic renal cell carcinoma with polyinosinic-polycytidylic acid
Laber et al. A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma
JP4721488B2 (ja) 腎細胞ガン処置
JP2022551672A (ja) 乳癌治療法
US20020009428A1 (en) Combination therapy for cancer
JP2007169300A (ja) 進行癌の処置のためのテモゾロミドとα−ＩＦＮの組合せ
CN101466395A (zh) 胸腺素α1制备用于治疗恶性黑色素瘤第Ⅳ期的药物中的用途
WO2023281413A1 (en) Methods and dosing regimens comprising pf-06873600 for the treatment of cancer
Hanssen et al. Extended Experience with Recombinant a-2b Interferon with OR Without Hepatic Artery Embolization in the Treatment OF Midgut Carcinoid Tumours A preliminary report
JPH09510737A (ja) 化学療法剤を増強するためのｉｌ−４の使用
KR20000010880A (ko) 종양에 대한 숙주 방어 기작의 자극
WO2026006187A1 (en) Composition and method of treating t-cell lymphoma
HK1129840A (en) Use of thymosin alpha 1 for preparing a medicament for the treatment of stage iv malignant melanoma
WO2023245248A1 (en) Treatment of melanoma
Cao et al. Biochemotherapy with low doses of subcutaneous interleukin-2 in patients with melanoma: results of a phase II trial
CN121003695A (zh) 抗tigit抗体和抗pd-1抗体联合治疗肿瘤
CN119997967A (zh) C/EBP-β拮抗剂和免疫调节剂的使用
Hanssen et al. EXTENDED EXPERIENCE WITH RECOMBINANT a-2b INTERFERON WITH OR WITHOUT HEPATIC ARTERY EMBOLIZATION IN THE TREATMENT OF MIDGUT CARCINOID TUMOURS
EP1908477A2 (en) Combination of temozolomide and pegylated interferon-alpha for treating cancer
WO2004073719A1 (en) A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100416

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100416

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20110218

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20120605